Dr. Ana Gomes, a postdoctoral scientist in the Harvard lab, found that by administering a compound that cells transform into NAD, the broken network can be repaired and communication and mitochondrial function rapidly restored. If the compound was given early enough, some aspects of the aging process could be reversed. She told the BBC that the research group wants to begin clinical trials in 2015:

Dr. Gomes said human therapies were a distant prospect but: "From what we know so far we don't think you'd have to take it from 20 years until we die.

"It seems we can start when we're already old, but not too old that we're already damaged.

"If started at 40 you would probably have a much nicer window of health aging — but I would guess that, we have to do clinical trials."

Meanwhile, in another development, scientists at the Buck Institute for Research on Aging in Novato announced they have found a way to vastly expand the lifespan of nematodes, or roundworms, by combining "mutations in two pathways well-known for lifespan extension." The researchers hypothesized that the worms' lifespan would increase by about 130 percent. Instead, their lifespan increased by five times -- meaning the nematodes lived to the human equivalent of 400 to 500 years.

The research, published in a paper Cell Reports on Dec. 12, "was kind of a shock," said Pankaj Kapahi, lead scientist on the study and a Buck faculty member, to the Marin Independent Journal:

Kapahi said in addition to implications for human life extension, the study's results could also lead to new approaches for battling age-related diseases such as Alzheimer's and Parkinson's. Kapahi said the research suggests the possibility of employing combination therapies for aging in much the same way as is done for cancer and HIV.

There have also been two recent developments in who is funding anti-aging research, both in Silicon Valley.

Such funding took a major hit last August when the Ellison Medical Foundation, with Oracle's Larry Ellison's as its chair, decided to stop making new grants, after 15 years as one of the leading sources of funding in the field.

As reported in San Francisco Business Times last week, this came as a shock to researchers, who had come to depend on the foundation's 4-year awards. Established in 1997, the foundation has awarded nearly $430 million in grants, with an estimated 80 percent of that going to anti-aging researchers -- including those at Stanford, UC Berkeley and the Buck Institute.

But a Google-backed venture, Calico, looks to have come to the rescue. Calico was formed three months ago to focus on anti-aging research. CEO -- and former Genentech CEO -- Arthur Levinson recently recruited some of the biggest names in the industry, including Roche chief medical officer Hal Barron and David Botstein, of the Lewis-Sigler Institute for Integrative Genomics (both Genentech alums), and UC San Francisco researcher/professor Dr. Cynthia Kenyon.

Buck InstituteBuck Institute

In Anti-Aging Breakthroughs, Scientists Reverse Aging in Mice, Worms